Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Status unconfirmed · Phase 2
Conditions studied: Kidney Cancer
In brief
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells to kill tumor cells. Giving bevacizumab together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with interleukin-2 works in treating patients with metastatic kidney cancer.
Key facts
- Study ID
- NCT00301990
- Run by
- Jonsson Comprehensive Cancer Center
- People needed
- 65
- Starts
- 2005-09-01
- Last updated by the study team
- 2014-01-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States (enrolling)
- Cardinal Bernardin Cancer Center at Loyola University Medical Center — Maywood, Illinois, United States (enrolling)
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States (enrolling)
- Our Lady of Mercy Medical Center Comprehensive Cancer Center — The Bronx, New York, United States (enrolling)
- Providence Cancer Center at Providence Portland Medical Center — Portland, Oregon, United States (enrolling)
- UPMC Cancer Centers — Pittsburgh, Pennsylvania, United States (enrolling)
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States (enrolling)
- University of Virginia Cancer Center — Charlottesville, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.